Abdenoflast

Small molecule

Also known as VTX2735

Phase 2Mechanism not established

Automated registry profile: compiled from public clinical-trial and regulatory records; not yet individually analyst-verified.

Earlyevidence

Evidence outlook

Mid-stage studies underway, no completed readout

Phase 2 studies are registered but none has completed a readout, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 2 (2)
Recurrent Pericarditis
NCT06836232 · Zomagen Biosciences Ltd.
2025-01-28 – 2027-10 · Recurrent Pericarditis
What this study did
Other / comorbidity
NCT05812781 · Zomagen Biosciences Ltd.
2023-03-18 – 2024-03-06 · Cryopyrin Associated Periodic Syndrome
What this study did

Competitive landscape

No competitors sharing a mechanism or indication in the current universe.

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Abdenoflast to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
October 2027 (1)
Phase 2Recurrent PericarditisRecruiting
Est. primary completion 2027-10 · NCT06836232 · CT.gov ↗
What to watch

See the full readout calendar ↗